A Study of Nivolumab in Selected Uterine Cancer Patients
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.
Uterine Cancer|Endometrial Carcinoma|Carcinosarcoma|Leiomyosarcoma|Undifferentiated Sarcoma|High Grade Endometrial Stromal Sarcoma|Clear Cell Carcinoma
DRUG: Nivolumab
Progression-Free Survival, will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1), at 24 weeks
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.